Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.

ABSTRACT: The field of oncolytic virotherapy has seen remarkable advancements in last two decades, leading to approval of the first oncolytic immuno-virotherapy, Talimogene Laherparepvec, for the treatment of melanoma. A plethora of preclinical and clinical studies have demonstrated excellent safety profiles of other oncolytic viruses. While oncolytic viruses show clinical promise in already immunogenic malignancies, response rates are inconsistent. Response rates are even less consistent in immunosuppressed tumor microenvironments like those found in liver, pancreas, and MSI-stable colon cancers. Therefore, the efficacy of oncolytic viruses needs to be improved for more oncolytic viruses to enter mainstream cancer therapy. One approach to increase the therapeutic efficacy of oncolytic viruses is to

SUBMITTER: Chaurasiya S 

PROVIDER: S-EPMC7352900 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature